Literature DB >> 9597282

The clinical role of specific IgE and IgG4 antibodies in patients having immunotherapy for seasonal allergic rhinitis.

Y Ohashi1, Y Nakai, A Tanaka, Y Kakinoki, T Masamoto, A Kato, H Sakamoto.   

Abstract

This study was designed to investigate the clinical role of specific IgG4 and IgE responses in patients during immunotherapy for seasonal allergy. The study included 109 patients with seasonal allergic rhinitis due to Japanese cedar pollens. They were divided into the control group and the immunotherapy group. Serum samples were obtained at the start of immunotherapy, before the pollen season and during the season, to determine serum specific IgE and IgG4. In the control group specific IgE was significantly increased, but specific IgG4 was not changed during the pollen season. In the immunotherapy group specific IgE was not significantly increased, but specific IgG4 was significantly increased during the season. In the patients having immunotherapy for 2 years or less, the seasonal increase in specific IgG4 related to the magnitude of the clinical effect. In the patients having immunotherapy for 3 years or more, the seasonal increase in specific IgE related to the magnitude of the clinical effect. In conclusion, the specific IgG4 response and specific IgE response during the pollen season make a significant contribution to the clinical effect of immunotherapy. However, modulation of specific IgE and IgG4 responses out of the pollen season was unlikely to be an important phenomenon related to the clinical effect of immunotherapy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9597282     DOI: 10.1046/j.1365-2273.1998.00115.x

Source DB:  PubMed          Journal:  Clin Otolaryngol Allied Sci        ISSN: 0307-7772


  1 in total

1.  Sublingual Immunotherapy Decreases Expression of Interleukin-33 in Children with Allergic Rhinitis.

Authors:  Yuanming Wang; Chuling Li; Yaxiong Xu; Deyu Xu; Gang Yang; Fang Liao; Xianglin Luo
Journal:  Indian J Pediatr       Date:  2018-05-23       Impact factor: 1.967

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.